Sunshine Lake Pharma Co., Ltd. Granted H Share Full Circulation Listing Approval
Sunshine Lake Pharma Co., Ltd. (Stock Code: 6887), a leading pharmaceutical company incorporated in the People’s Republic of China, has announced a significant development regarding its share capital structure that is likely to be highly relevant to shareholders and investors.
Key Highlights
- Listing Approval Granted: The Stock Exchange of Hong Kong Limited has granted approval for the listing and permission to deal in 208,390,308 H Shares (the “Converted H Shares”), which have been converted from Domestic Shares as part of the company’s H Share Full Circulation initiative. The approval was granted on 5 May 2026.
- Significant Change in Shareholding Structure: The conversion involves 29 participating shareholders, collectively representing approximately 36.14% of the company’s total issued share capital (including treasury shares).
- Post-Conversion Share Structure: Upon completion of the conversion and listing, the company’s H Shares will increase from 19.55% to 55.68% of the total issued shares, while Domestic Shares will decrease from 80.45% to 44.32%.
- Potential Impact: This transition enhances the liquidity of Sunshine Lake Pharma’s H Shares and could have a material impact on the share price and market dynamics, as more shares become freely tradable in the Hong Kong market.
Details of the Share Conversion
The H Share Full Circulation program allows Domestic Shares in Chinese companies listed in Hong Kong to be converted into H Shares and traded on the Hong Kong Stock Exchange. Sunshine Lake Pharma’s move to convert and list 208,390,308 Domestic Shares as H Shares is a significant step in aligning the interests of its domestic and international investors and improving share liquidity.
List of Major Participating Shareholders and their Converted H Shares:
- Shenzhen HEC Industrial Development Co., Ltd. – 29,745,526 shares (5.16%)
- Guangdong HEC Technology Holding Co., Ltd. – 50,989,649 shares (8.84%)
- Yidu Shuaixinwei Equity Investment Limited (L.P.) – 30,607,250 shares (5.31%)
- Jiaxing Xingsheng Dongyan Investment Partnership (L.P.) – 9,679,689 shares (1.68%)
- Total number of participating shareholders: 29, with shareholdings ranging from approximately 0.08% to 8.84% each.
Shareholding Structure Before and After Conversion
| Type of Shares | Before Conversion (No. of Shares, %) |
After Conversion (No. of Shares, %) |
|---|---|---|
| Domestic Shares | 463,943,215 (80.45%) | 255,552,907 (44.32%) |
| H Shares | 112,712,832 (19.55%) | 321,103,140 (55.68%) |
| Total | 576,656,047 (100%) | 576,656,047 (100%) |
Investor Takeaways & Price-Sensitive Information
- Material Increase in Tradable Shares: The substantial increase in H Shares (from 19.55% to 55.68%) will significantly enhance the liquidity and tradability of Sunshine Lake Pharma’s shares on the Hong Kong Stock Exchange, which can attract more institutional and international investors.
- Potential Impact on Share Price: The greater free float may lead to increased trading volumes, potentially affecting the share price, especially in the short term. Investors should monitor the market response closely.
- Shareholder Caution Advised: The company has explicitly advised shareholders and potential investors to exercise caution when dealing in the shares, indicating that the changes may result in price volatility as the market digests the new share structure.
- Further Announcements Expected: Sunshine Lake Pharma will provide updates on the progress of the conversion and listing procedures and any other regulatory requirements.
Board and Governance
The board of Sunshine Lake Pharma currently comprises two executive directors (Dr. Zhang Yingjun and Dr. Li Wenjia), six non-executive directors, and five independent non-executive directors, indicating a robust governance structure.
Conclusion
The approval for full circulation of H Shares marks a pivotal moment for Sunshine Lake Pharma Co., Ltd. This development increases the company’s exposure to global capital markets, enhances liquidity, and could materially impact the company’s share value. Shareholders and investors are encouraged to stay alert for further updates and monitor the share price closely as the conversion and listing process unfolds.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own research or consult with a professional advisor before making investment decisions. The information provided is based on company announcements and may be subject to change.
